Direct Healthcare Professional Communication (DHPC) on Mavenclad (cladribine): risk of serious liver injury and new recommendations about liver function monitoring
2022.02.16
Active substance: cladribine
Merck Healthcare KGaA in agreement with the European Medicines Agency and the Federal Institute for Drugs and Medical Devices would like to inform you about adverse events of liver injury , including serious cases, under the treatment with Mavenclad. Before initiating treatment, a detailed patient history of underlying liver disorders or episodes of liver injury with other medicines should be undertaken.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN